MX2013011888A - Composiciones y metodos para inhibir y/o modular las celulas-t efectoras involucradas en la enfermedad neurodegenerativa inflamatoria. - Google Patents

Info

Publication number

MX2013011888A

MX2013011888A MX2013011888A MX2013011888A MX2013011888A MX 2013011888 A MX2013011888 A MX 2013011888A MX 2013011888 A MX2013011888 A MX 2013011888A MX 2013011888 A MX2013011888 A MX 2013011888A MX 2013011888 A MX2013011888 A MX 2013011888A

Authority

MX

Mexico

Prior art keywords

cells

disease

inflammatory

fluid

vivo

Prior art date

2011-04-13

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title claims abstract description 155
• 230000002757 inflammatory effect Effects 0.000 title claims abstract description 85
• 230000004770 neurodegeneration Effects 0.000 title claims abstract description 56
• 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 55
• 210000003162 effector t lymphocyte Anatomy 0.000 title claims abstract description 46
• 230000002401 inhibitory effect Effects 0.000 title claims description 19
• 239000000203 mixture Substances 0.000 title abstract description 99
• 239000012530 fluid Substances 0.000 claims abstract description 295
• 210000004027 cell Anatomy 0.000 claims abstract description 257
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 125
• 239000001301 oxygen Substances 0.000 claims abstract description 125
• 229910052760 oxygen Inorganic materials 0.000 claims abstract description 125
• 230000000694 effects Effects 0.000 claims abstract description 120
• 208000024891 symptom Diseases 0.000 claims abstract description 47
• 238000002560 therapeutic procedure Methods 0.000 claims abstract description 14
• 238000002648 combination therapy Methods 0.000 claims abstract description 8
• 230000003614 tolerogenic effect Effects 0.000 claims abstract description 6
• 201000006417 multiple sclerosis Diseases 0.000 claims description 130
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 102
• 239000007789 gas Substances 0.000 claims description 94
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 88
• 201000010099 disease Diseases 0.000 claims description 84
• 239000002086 nanomaterial Substances 0.000 claims description 83
• 239000000243 solution Substances 0.000 claims description 70
• 210000000170 cell membrane Anatomy 0.000 claims description 55
• 210000000612 antigen-presenting cell Anatomy 0.000 claims description 54
• 239000003814 drug Substances 0.000 claims description 49
• 210000003289 regulatory T cell Anatomy 0.000 claims description 49
• 230000001965 increasing effect Effects 0.000 claims description 46
• 230000004054 inflammatory process Effects 0.000 claims description 45
• 108090000623 proteins and genes Proteins 0.000 claims description 45
• 206010061218 Inflammation Diseases 0.000 claims description 42
• 230000006870 function Effects 0.000 claims description 42
• 230000000626 neurodegenerative effect Effects 0.000 claims description 38
• 210000003169 central nervous system Anatomy 0.000 claims description 35
• 102000004169 proteins and genes Human genes 0.000 claims description 35
• 210000004443 dendritic cell Anatomy 0.000 claims description 33
• 229940124597 therapeutic agent Drugs 0.000 claims description 32
• 208000024827 Alzheimer disease Diseases 0.000 claims description 28
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 27
• 210000004369 blood Anatomy 0.000 claims description 27
• 239000008280 blood Substances 0.000 claims description 27
• 108010072051 Glatiramer Acetate Proteins 0.000 claims description 25
• FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims description 25
• -1 artformoterol Chemical compound 0.000 claims description 25
• 230000014509 gene expression Effects 0.000 claims description 25
• 229960003776 glatiramer acetate Drugs 0.000 claims description 25
• 108090000467 Interferon-beta Proteins 0.000 claims description 23
• 102000003996 Interferon-beta Human genes 0.000 claims description 22
• 239000000427 antigen Substances 0.000 claims description 22
• 108091007433 antigens Proteins 0.000 claims description 22
• 102000036639 antigens Human genes 0.000 claims description 22
• 238000001727 in vivo Methods 0.000 claims description 22
• 239000012528 membrane Substances 0.000 claims description 22
• 229960001388 interferon-beta Drugs 0.000 claims description 21
• 208000018737 Parkinson disease Diseases 0.000 claims description 20
• 210000004556 brain Anatomy 0.000 claims description 20
• 230000005764 inhibitory process Effects 0.000 claims description 20
• 239000007864 aqueous solution Substances 0.000 claims description 19
• 239000011575 calcium Substances 0.000 claims description 19
• 208000010877 cognitive disease Diseases 0.000 claims description 19
• 238000011161 development Methods 0.000 claims description 19
• 230000003834 intracellular effect Effects 0.000 claims description 19
• 229960005027 natalizumab Drugs 0.000 claims description 19
• 238000000338 in vitro Methods 0.000 claims description 18
• 229960001156 mitoxantrone Drugs 0.000 claims description 18
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 18
• 102000005962 receptors Human genes 0.000 claims description 18
• 108020003175 receptors Proteins 0.000 claims description 18
• 230000001413 cellular effect Effects 0.000 claims description 17
• 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims description 16
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 15
• 102100038497 Cytokine receptor-like factor 2 Human genes 0.000 claims description 15
• 208000016192 Demyelinating disease Diseases 0.000 claims description 15
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims description 15
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims description 15
• 229910052791 calcium Inorganic materials 0.000 claims description 15
• 230000001419 dependent effect Effects 0.000 claims description 15
• 229940079593 drug Drugs 0.000 claims description 15
• 230000004968 inflammatory condition Effects 0.000 claims description 15
• 150000002500 ions Chemical class 0.000 claims description 15
• 238000001990 intravenous administration Methods 0.000 claims description 14
• 150000003839 salts Chemical class 0.000 claims description 14
• 230000006378 damage Effects 0.000 claims description 13
• 108091006027 G proteins Proteins 0.000 claims description 12
• 102000030782 GTP binding Human genes 0.000 claims description 12
• 108091000058 GTP-Binding Proteins 0.000 claims description 12
• 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims description 12
• 208000027418 Wounds and injury Diseases 0.000 claims description 12
• 230000031146 intracellular signal transduction Effects 0.000 claims description 12
• 108010052285 Membrane Proteins Proteins 0.000 claims description 11
• 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 11
• 208000024777 Prion disease Diseases 0.000 claims description 11
• 208000030507 AIDS Diseases 0.000 claims description 10
• 101710194733 Cytokine receptor-like factor 2 Proteins 0.000 claims description 10
• 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 claims description 10
• 241000124008 Mammalia Species 0.000 claims description 10
• 102100031294 Thymic stromal lymphopoietin Human genes 0.000 claims description 10
• 102000030621 adenylate cyclase Human genes 0.000 claims description 10
• 108060000200 adenylate cyclase Proteins 0.000 claims description 10
• 210000003630 histaminocyte Anatomy 0.000 claims description 10
• 239000003112 inhibitor Substances 0.000 claims description 10
• 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims description 9
• 208000023105 Huntington disease Diseases 0.000 claims description 9
• 108090000862 Ion Channels Proteins 0.000 claims description 9
• 102000004310 Ion Channels Human genes 0.000 claims description 9
• 102000018697 Membrane Proteins Human genes 0.000 claims description 9
• 208000019695 Migraine disease Diseases 0.000 claims description 9
• 230000001684 chronic effect Effects 0.000 claims description 9
• 239000003246 corticosteroid Substances 0.000 claims description 9
• 229960001334 corticosteroids Drugs 0.000 claims description 9
• 206010027599 migraine Diseases 0.000 claims description 9
• 230000009885 systemic effect Effects 0.000 claims description 9
• 208000006011 Stroke Diseases 0.000 claims description 8
• 208000027061 mild cognitive impairment Diseases 0.000 claims description 8
• 210000001616 monocyte Anatomy 0.000 claims description 8
• 230000003959 neuroinflammation Effects 0.000 claims description 8
• 230000010287 polarization Effects 0.000 claims description 8
• 230000002195 synergetic effect Effects 0.000 claims description 8
• VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 7
• 230000027455 binding Effects 0.000 claims description 7
• 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 7
• 230000006999 cognitive decline Effects 0.000 claims description 7
• 210000000987 immune system Anatomy 0.000 claims description 7
• 208000014674 injury Diseases 0.000 claims description 7
• 208000028867 ischemia Diseases 0.000 claims description 7
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
• 102000027257 transmembrane receptors Human genes 0.000 claims description 7
• 108091008578 transmembrane receptors Proteins 0.000 claims description 7
• 102100026802 72 kDa type IV collagenase Human genes 0.000 claims description 6
• RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 claims description 6
• 206010019196 Head injury Diseases 0.000 claims description 6
• 208000038016 acute inflammation Diseases 0.000 claims description 6
• 230000006022 acute inflammation Effects 0.000 claims description 6
• NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 6
• 229940121363 anti-inflammatory agent Drugs 0.000 claims description 6
• 239000002260 anti-inflammatory agent Substances 0.000 claims description 6
• 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims description 6
• 208000025698 brain inflammatory disease Diseases 0.000 claims description 6
• 229960004436 budesonide Drugs 0.000 claims description 6
• 239000000812 cholinergic antagonist Substances 0.000 claims description 6
• 208000037976 chronic inflammation Diseases 0.000 claims description 6
• 230000003247 decreasing effect Effects 0.000 claims description 6
• 206010014599 encephalitis Diseases 0.000 claims description 6
• 210000002889 endothelial cell Anatomy 0.000 claims description 6
• BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 6
• 229960002848 formoterol Drugs 0.000 claims description 6
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 6
• 230000001939 inductive effect Effects 0.000 claims description 6
• 229960001888 ipratropium Drugs 0.000 claims description 6
• OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 claims description 6
• 150000002617 leukotrienes Chemical class 0.000 claims description 6
• 239000003607 modifier Substances 0.000 claims description 6
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
• 229960002052 salbutamol Drugs 0.000 claims description 6
• 210000000278 spinal cord Anatomy 0.000 claims description 6
• 239000003381 stabilizer Substances 0.000 claims description 6
• ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 6
• 101710151806 72 kDa type IV collagenase Proteins 0.000 claims description 5
• 101000956427 Homo sapiens Cytokine receptor-like factor 2 Proteins 0.000 claims description 5
• GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 5
• 239000005557 antagonist Substances 0.000 claims description 5
• 210000001130 astrocyte Anatomy 0.000 claims description 5
• 230000003197 catalytic effect Effects 0.000 claims description 5
• 230000006020 chronic inflammation Effects 0.000 claims description 5
• 229960002714 fluticasone Drugs 0.000 claims description 5
• MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 5
• 239000003862 glucocorticoid Substances 0.000 claims description 5
• 210000005036 nerve Anatomy 0.000 claims description 5
• 230000003472 neutralizing effect Effects 0.000 claims description 5
• 229960004017 salmeterol Drugs 0.000 claims description 5
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 4
• 108010036949 Cyclosporine Proteins 0.000 claims description 4
• 229940124761 MMP inhibitor Drugs 0.000 claims description 4
• 102000014384 Type C Phospholipases Human genes 0.000 claims description 4
• 108010079194 Type C Phospholipases Proteins 0.000 claims description 4
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 4
• 229960002170 azathioprine Drugs 0.000 claims description 4
• 230000021164 cell adhesion Effects 0.000 claims description 4
• 229960001265 ciclosporin Drugs 0.000 claims description 4
• 229930182912 cyclosporin Natural products 0.000 claims description 4
• 230000002999 depolarising effect Effects 0.000 claims description 4
• 108010044426 integrins Proteins 0.000 claims description 4
• 102000006495 integrins Human genes 0.000 claims description 4
• 239000003446 ligand Substances 0.000 claims description 4
• 210000002501 natural regulatory T cell Anatomy 0.000 claims description 4
• 230000002685 pulmonary effect Effects 0.000 claims description 4
• 230000009467 reduction Effects 0.000 claims description 4
• NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 claims description 3
• 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 claims description 3
• ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims description 3
• 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 claims description 3
• VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 claims description 3
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 3
• YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 claims description 3
• 238000009098 adjuvant therapy Methods 0.000 claims description 3
• 229940125715 antihistaminic agent Drugs 0.000 claims description 3
• 239000000739 antihistaminic agent Substances 0.000 claims description 3
• 230000004888 barrier function Effects 0.000 claims description 3
• 229940092705 beclomethasone Drugs 0.000 claims description 3
• NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims description 3
• 229940124748 beta 2 agonist Drugs 0.000 claims description 3
• 229960001803 cetirizine Drugs 0.000 claims description 3
• 229940000425 combination drug Drugs 0.000 claims description 3
• 210000001047 desmosome Anatomy 0.000 claims description 3
• 229960000520 diphenhydramine Drugs 0.000 claims description 3
• 210000003038 endothelium Anatomy 0.000 claims description 3
• 229960000676 flunisolide Drugs 0.000 claims description 3
• 108020001507 fusion proteins Proteins 0.000 claims description 3
• 102000037865 fusion proteins Human genes 0.000 claims description 3
• 229960000890 hydrocortisone Drugs 0.000 claims description 3
• 229960000930 hydroxyzine Drugs 0.000 claims description 3
• ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 claims description 3
• 230000000968 intestinal effect Effects 0.000 claims description 3
• 229950008204 levosalbutamol Drugs 0.000 claims description 3
• 229940127212 long-acting beta 2 agonist Drugs 0.000 claims description 3
• 229960003088 loratadine Drugs 0.000 claims description 3
• JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims description 3
• 229960001664 mometasone Drugs 0.000 claims description 3
• QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims description 3
• RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims description 3
• 229960004866 mycophenolate mofetil Drugs 0.000 claims description 3
• RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 claims description 3
• 229960004398 nedocromil Drugs 0.000 claims description 3
• 230000037361 pathway Effects 0.000 claims description 3
• 239000002504 physiological saline solution Substances 0.000 claims description 3
• KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 claims description 3
• 229960005330 pimecrolimus Drugs 0.000 claims description 3
• 229960005414 pirbuterol Drugs 0.000 claims description 3
• 229920001184 polypeptide Polymers 0.000 claims description 3
• 229960005205 prednisolone Drugs 0.000 claims description 3
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 3
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 3
• 229960004618 prednisone Drugs 0.000 claims description 3
• MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims description 3
• 229960001967 tacrolimus Drugs 0.000 claims description 3
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 3
• 229960000278 theophylline Drugs 0.000 claims description 3
• 210000001578 tight junction Anatomy 0.000 claims description 3
• LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 claims description 3
• 229940110309 tiotropium Drugs 0.000 claims description 3
• 229960005294 triamcinolone Drugs 0.000 claims description 3
• GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims description 3
• MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 claims description 3
• 229960005332 zileuton Drugs 0.000 claims description 3
• 102100024167 C-C chemokine receptor type 3 Human genes 0.000 claims description 2
• 229930105110 Cyclosporin A Natural products 0.000 claims description 2
• 230000001464 adherent effect Effects 0.000 claims description 2
• 229940127211 short-acting beta 2 agonist Drugs 0.000 claims description 2
• 150000003431 steroids Chemical class 0.000 claims description 2
• 101710149862 C-C chemokine receptor type 3 Proteins 0.000 claims 1
• ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims 1
• 229940021615 salmeterol and budesonide Drugs 0.000 claims 1
• 229940021597 salmeterol and fluticasone Drugs 0.000 claims 1
• 210000001744 T-lymphocyte Anatomy 0.000 abstract description 55
• 230000001225 therapeutic effect Effects 0.000 abstract description 46
• 238000011282 treatment Methods 0.000 description 89
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 81
• 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 73
• 102000004127 Cytokines Human genes 0.000 description 68
• 108090000695 Cytokines Proteins 0.000 description 68
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 59
• 241001465754 Metazoa Species 0.000 description 56
• 239000000463 material Substances 0.000 description 56
• 239000003981 vehicle Substances 0.000 description 54
• 239000011780 sodium chloride Substances 0.000 description 48
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 45
• 238000009472 formulation Methods 0.000 description 42
• KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 39
• 238000002474 experimental method Methods 0.000 description 39
• 102000047918 Myelin Basic Human genes 0.000 description 38
• 101710107068 Myelin basic protein Proteins 0.000 description 37
• 229910001868 water Inorganic materials 0.000 description 37
• 241000700159 Rattus Species 0.000 description 35
• 210000000265 leukocyte Anatomy 0.000 description 31
• 235000018102 proteins Nutrition 0.000 description 31
• 230000037396 body weight Effects 0.000 description 30
• 238000012360 testing method Methods 0.000 description 30
• 238000002156 mixing Methods 0.000 description 29
• 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 28
• 241000699670 Mus sp. Species 0.000 description 26
• 210000004698 lymphocyte Anatomy 0.000 description 26
• 210000000440 neutrophil Anatomy 0.000 description 24
• 102000013691 Interleukin-17 Human genes 0.000 description 21
• 108050003558 Interleukin-17 Proteins 0.000 description 21
• 230000004913 activation Effects 0.000 description 21
• 239000004480 active ingredient Substances 0.000 description 21
• 239000007924 injection Substances 0.000 description 20
• 238000002347 injection Methods 0.000 description 20
• 210000004379 membrane Anatomy 0.000 description 20
• 238000004458 analytical method Methods 0.000 description 19
• 150000001875 compounds Chemical class 0.000 description 19
• 239000000843 powder Substances 0.000 description 19
• 229960003957 dexamethasone Drugs 0.000 description 18
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 18
• 210000002540 macrophage Anatomy 0.000 description 18
• 230000007423 decrease Effects 0.000 description 17
• 230000018109 developmental process Effects 0.000 description 17
• 230000006698 induction Effects 0.000 description 17
• 239000002609 medium Substances 0.000 description 17
• 230000000770 proinflammatory effect Effects 0.000 description 17
• 230000004044 response Effects 0.000 description 16
• 210000001519 tissue Anatomy 0.000 description 16
• 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 15
• 108090001007 Interleukin-8 Proteins 0.000 description 15
• 102000004890 Interleukin-8 Human genes 0.000 description 15
• 238000011534 incubation Methods 0.000 description 15
• 238000004519 manufacturing process Methods 0.000 description 15
• 230000002829 reductive effect Effects 0.000 description 15
• 230000004071 biological effect Effects 0.000 description 14
• 108090001005 Interleukin-6 Proteins 0.000 description 13
• 102000002274 Matrix Metalloproteinases Human genes 0.000 description 13
• 108010000684 Matrix Metalloproteinases Proteins 0.000 description 13
• 230000015572 biosynthetic process Effects 0.000 description 13
• 230000008506 pathogenesis Effects 0.000 description 13
• 208000023275 Autoimmune disease Diseases 0.000 description 12
• 230000001154 acute effect Effects 0.000 description 12
• 230000003110 anti-inflammatory effect Effects 0.000 description 12
• 230000002354 daily effect Effects 0.000 description 12
• 230000028709 inflammatory response Effects 0.000 description 12
• 239000006228 supernatant Substances 0.000 description 12
• 102000004190 Enzymes Human genes 0.000 description 11
• 108090000790 Enzymes Proteins 0.000 description 11
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
• 241000282414 Homo sapiens Species 0.000 description 11
• 102000004889 Interleukin-6 Human genes 0.000 description 11
• 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 11
• 102100023302 Myelin-oligodendrocyte glycoprotein Human genes 0.000 description 11
• 239000000443 aerosol Substances 0.000 description 11
• 230000033228 biological regulation Effects 0.000 description 11
• 239000003795 chemical substances by application Substances 0.000 description 11
• 229940088598 enzyme Drugs 0.000 description 11
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 11
• 208000027866 inflammatory disease Diseases 0.000 description 11
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
• 108010035532 Collagen Proteins 0.000 description 10
• 102000008186 Collagen Human genes 0.000 description 10
• 102000006386 Myelin Proteins Human genes 0.000 description 10
• 108010083674 Myelin Proteins Proteins 0.000 description 10
• 206010052428 Wound Diseases 0.000 description 10
• 208000006673 asthma Diseases 0.000 description 10
• 230000008499 blood brain barrier function Effects 0.000 description 10
• 210000001218 blood-brain barrier Anatomy 0.000 description 10
• 230000008859 change Effects 0.000 description 10
• 229920001436 collagen Polymers 0.000 description 10
• 230000028327 secretion Effects 0.000 description 10
• 230000000638 stimulation Effects 0.000 description 10
• 102000005741 Metalloproteases Human genes 0.000 description 9
• 108010006035 Metalloproteases Proteins 0.000 description 9
• 108010058846 Ovalbumin Proteins 0.000 description 9
• 108700012920 TNF Proteins 0.000 description 9
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
• 238000003556 assay Methods 0.000 description 9
• 150000001768 cations Chemical class 0.000 description 9
• 239000003937 drug carrier Substances 0.000 description 9
• 239000001963 growth medium Substances 0.000 description 9
• 210000005012 myelin Anatomy 0.000 description 9
• 229940092253 ovalbumin Drugs 0.000 description 9
• 230000035755 proliferation Effects 0.000 description 9
• 206010020751 Hypersensitivity Diseases 0.000 description 8
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 8
• AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 8
• 208000007118 chronic progressive multiple sclerosis Diseases 0.000 description 8
• 210000002950 fibroblast Anatomy 0.000 description 8
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 8
• 230000007246 mechanism Effects 0.000 description 8
• 230000001105 regulatory effect Effects 0.000 description 8
• 238000007920 subcutaneous administration Methods 0.000 description 8
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 7
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 7
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 7
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 7
• 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 7
• 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 7
• 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 7
• 102000000589 Interleukin-1 Human genes 0.000 description 7
• 108010002352 Interleukin-1 Proteins 0.000 description 7
• 108090000978 Interleukin-4 Proteins 0.000 description 7
• 102000004388 Interleukin-4 Human genes 0.000 description 7
• 206010028980 Neoplasm Diseases 0.000 description 7
• 239000004698 Polyethylene Substances 0.000 description 7
• 230000000274 adsorptive effect Effects 0.000 description 7
• 238000010171 animal model Methods 0.000 description 7
• 150000001450 anions Chemical class 0.000 description 7
• 230000015556 catabolic process Effects 0.000 description 7
• 230000001427 coherent effect Effects 0.000 description 7
• 239000003085 diluting agent Substances 0.000 description 7
• 239000000839 emulsion Substances 0.000 description 7
• 239000000499 gel Substances 0.000 description 7
• 210000002865 immune cell Anatomy 0.000 description 7
• 239000007788 liquid Substances 0.000 description 7
• 238000005259 measurement Methods 0.000 description 7
• 210000002569 neuron Anatomy 0.000 description 7
• 230000010355 oscillation Effects 0.000 description 7
• 230000002093 peripheral effect Effects 0.000 description 7
• 230000000069 prophylactic effect Effects 0.000 description 7
• 238000011552 rat model Methods 0.000 description 7
• 239000007787 solid Substances 0.000 description 7
• 239000000725 suspension Substances 0.000 description 7
• 239000003826 tablet Substances 0.000 description 7
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 6
• MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 6
• OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 6
• 108010065805 Interleukin-12 Proteins 0.000 description 6
• 241000699666 Mus <mouse, genus> Species 0.000 description 6
• 102000035195 Peptidases Human genes 0.000 description 6
• 108091005804 Peptidases Proteins 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• 206010040070 Septic Shock Diseases 0.000 description 6
• 239000003570 air Substances 0.000 description 6
• 208000026935 allergic disease Diseases 0.000 description 6
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 6
• 206010002022 amyloidosis Diseases 0.000 description 6
• 230000001363 autoimmune Effects 0.000 description 6
• 239000002585 base Substances 0.000 description 6
• 239000001110 calcium chloride Substances 0.000 description 6
• 235000011148 calcium chloride Nutrition 0.000 description 6
• 229910001628 calcium chloride Inorganic materials 0.000 description 6
• 238000006243 chemical reaction Methods 0.000 description 6
• 238000006731 degradation reaction Methods 0.000 description 6
• 230000004069 differentiation Effects 0.000 description 6
• 235000019441 ethanol Nutrition 0.000 description 6
• 239000008187 granular material Substances 0.000 description 6
• 230000036571 hydration Effects 0.000 description 6
• 238000006703 hydration reaction Methods 0.000 description 6
• 230000036512 infertility Effects 0.000 description 6
• 230000005012 migration Effects 0.000 description 6
• 238000013508 migration Methods 0.000 description 6
• 239000008194 pharmaceutical composition Substances 0.000 description 6
• 239000000546 pharmaceutical excipient Substances 0.000 description 6
• 230000002265 prevention Effects 0.000 description 6
• 230000000750 progressive effect Effects 0.000 description 6
• 238000011321 prophylaxis Methods 0.000 description 6
• 208000020431 spinal cord injury Diseases 0.000 description 6
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 5
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 5
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
• 108091006146 Channels Proteins 0.000 description 5
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 5
• 206010012305 Demyelination Diseases 0.000 description 5
• 108010002350 Interleukin-2 Proteins 0.000 description 5
• 238000009739 binding Methods 0.000 description 5
• 210000000424 bronchial epithelial cell Anatomy 0.000 description 5
• 201000011510 cancer Diseases 0.000 description 5
• 239000000470 constituent Substances 0.000 description 5
• 239000006071 cream Substances 0.000 description 5
• 206010012601 diabetes mellitus Diseases 0.000 description 5
• 239000010432 diamond Substances 0.000 description 5
• 239000002552 dosage form Substances 0.000 description 5
• 210000002615 epidermis Anatomy 0.000 description 5
• 239000000835 fiber Substances 0.000 description 5
• 239000000796 flavoring agent Substances 0.000 description 5
• 230000035876 healing Effects 0.000 description 5
• 210000004072 lung Anatomy 0.000 description 5
• 230000001404 mediated effect Effects 0.000 description 5
• 229910052757 nitrogen Inorganic materials 0.000 description 5
• 239000002245 particle Substances 0.000 description 5
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
• 239000006187 pill Substances 0.000 description 5
• 239000003380 propellant Substances 0.000 description 5
• 238000012552 review Methods 0.000 description 5
• 206010039073 rheumatoid arthritis Diseases 0.000 description 5
• 210000002966 serum Anatomy 0.000 description 5
• 239000000126 substance Substances 0.000 description 5
• 230000026683 transduction Effects 0.000 description 5
• 238000010361 transduction Methods 0.000 description 5
• 230000008733 trauma Effects 0.000 description 5
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
• 241000416162 Astragalus gummifer Species 0.000 description 4
• 102100032367 C-C motif chemokine 5 Human genes 0.000 description 4
• 108010055166 Chemokine CCL5 Proteins 0.000 description 4
• 102000019034 Chemokines Human genes 0.000 description 4
• 108010012236 Chemokines Proteins 0.000 description 4
• 208000028698 Cognitive impairment Diseases 0.000 description 4
• 108010010803 Gelatin Proteins 0.000 description 4
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
• 241000282412 Homo Species 0.000 description 4
• 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 description 4
• 102000003816 Interleukin-13 Human genes 0.000 description 4
• 108090000176 Interleukin-13 Proteins 0.000 description 4
• 102100033461 Interleukin-17A Human genes 0.000 description 4
• 102000043131 MHC class II family Human genes 0.000 description 4
• 108091054438 MHC class II family Proteins 0.000 description 4
• 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 4
• 108050006599 Metalloproteinase inhibitor 1 Proteins 0.000 description 4
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 4
• 206010028813 Nausea Diseases 0.000 description 4
• 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 4
• 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 4
• 208000002193 Pain Diseases 0.000 description 4
• 206010070834 Sensitisation Diseases 0.000 description 4
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
• 229930006000 Sucrose Natural products 0.000 description 4
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
• 229920001615 Tragacanth Polymers 0.000 description 4
• 239000002671 adjuvant Substances 0.000 description 4
• 230000007815 allergy Effects 0.000 description 4
• 210000003050 axon Anatomy 0.000 description 4
• 210000004204 blood vessel Anatomy 0.000 description 4
• 239000000969 carrier Substances 0.000 description 4
• 238000004891 communication Methods 0.000 description 4
• 230000006854 communication Effects 0.000 description 4
• 239000008367 deionised water Substances 0.000 description 4
• 229910021641 deionized water Inorganic materials 0.000 description 4
• 230000003210 demyelinating effect Effects 0.000 description 4
• 208000035475 disorder Diseases 0.000 description 4
• 239000012153 distilled water Substances 0.000 description 4
• 238000009826 distribution Methods 0.000 description 4
• 231100000673 dose–response relationship Toxicity 0.000 description 4
• 239000003995 emulsifying agent Substances 0.000 description 4
• 230000001712 encephalitogenic effect Effects 0.000 description 4
• 238000005516 engineering process Methods 0.000 description 4
• 230000007613 environmental effect Effects 0.000 description 4
• 210000002919 epithelial cell Anatomy 0.000 description 4
• 210000000981 epithelium Anatomy 0.000 description 4
• 238000011156 evaluation Methods 0.000 description 4
• 239000008273 gelatin Substances 0.000 description 4
• 229920000159 gelatin Polymers 0.000 description 4
• 235000019322 gelatine Nutrition 0.000 description 4
• 235000011852 gelatine desserts Nutrition 0.000 description 4
• 230000002068 genetic effect Effects 0.000 description 4
• 230000012010 growth Effects 0.000 description 4
• 230000028993 immune response Effects 0.000 description 4
• 230000000977 initiatory effect Effects 0.000 description 4
• 230000015788 innate immune response Effects 0.000 description 4
• XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
• 230000003902 lesion Effects 0.000 description 4
• 238000012423 maintenance Methods 0.000 description 4
• 102000006240 membrane receptors Human genes 0.000 description 4
• 238000010172 mouse model Methods 0.000 description 4
• 230000008693 nausea Effects 0.000 description 4
• 239000003921 oil Substances 0.000 description 4
• 235000019198 oils Nutrition 0.000 description 4
• 239000006072 paste Substances 0.000 description 4
• 229920000642 polymer Polymers 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• 238000012545 processing Methods 0.000 description 4
• 239000012266 salt solution Substances 0.000 description 4
• 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 4
• 230000008313 sensitization Effects 0.000 description 4
• 229910001415 sodium ion Inorganic materials 0.000 description 4
• 239000002904 solvent Substances 0.000 description 4
• 230000002269 spontaneous effect Effects 0.000 description 4
• 239000005720 sucrose Substances 0.000 description 4
• 239000004094 surface-active agent Substances 0.000 description 4
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 4
• 230000000699 topical effect Effects 0.000 description 4
• 235000010487 tragacanth Nutrition 0.000 description 4
• 239000000196 tragacanth Substances 0.000 description 4
• 229940116362 tragacanth Drugs 0.000 description 4
• 238000011269 treatment regimen Methods 0.000 description 4
• LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 3
• VALKNOMNTXYCBM-UHFFFAOYSA-N 4-(4-phenoxyphenyl)sulfonylbutane-1,2-dithiol Chemical compound C1=CC(S(=O)(=O)CCC(S)CS)=CC=C1OC1=CC=CC=C1 VALKNOMNTXYCBM-UHFFFAOYSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
• 108010001857 Cell Surface Receptors Proteins 0.000 description 3
• 206010010904 Convulsion Diseases 0.000 description 3
• 206010012289 Dementia Diseases 0.000 description 3
• SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 3
• 201000004624 Dermatitis Diseases 0.000 description 3
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
• 238000002965 ELISA Methods 0.000 description 3
• 206010014561 Emphysema Diseases 0.000 description 3
• 206010014824 Endotoxic shock Diseases 0.000 description 3
• 102100023688 Eotaxin Human genes 0.000 description 3
• 101710139422 Eotaxin Proteins 0.000 description 3
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
• 102100027581 Forkhead box protein P3 Human genes 0.000 description 3
• 239000007995 HEPES buffer Substances 0.000 description 3
• 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 3
• 101001013648 Homo sapiens Methionine synthase Proteins 0.000 description 3
• 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 3
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 3
• 102100020881 Interleukin-1 alpha Human genes 0.000 description 3
• 102000003777 Interleukin-1 beta Human genes 0.000 description 3
• 108090000193 Interleukin-1 beta Proteins 0.000 description 3
• 108010002616 Interleukin-5 Proteins 0.000 description 3
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
• 102000004083 Lymphotoxin-alpha Human genes 0.000 description 3
• 108090000542 Lymphotoxin-alpha Proteins 0.000 description 3
• 102100027998 Macrophage metalloelastase Human genes 0.000 description 3
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
• 108010025020 Nerve Growth Factor Proteins 0.000 description 3
• 206010033799 Paralysis Diseases 0.000 description 3
• 206010067063 Progressive relapsing multiple sclerosis Diseases 0.000 description 3
• 206010037660 Pyrexia Diseases 0.000 description 3
• 101001018324 Rattus norvegicus Myelin basic protein Proteins 0.000 description 3
• 241000283984 Rodentia Species 0.000 description 3
• 206010040047 Sepsis Diseases 0.000 description 3
• 239000012163 TRI reagent Substances 0.000 description 3
• 108091023040 Transcription factor Proteins 0.000 description 3
• 102000040945 Transcription factor Human genes 0.000 description 3
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
• 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 3
• 230000033115 angiogenesis Effects 0.000 description 3
• 230000000890 antigenic effect Effects 0.000 description 3
• 239000003963 antioxidant agent Substances 0.000 description 3
• 208000010668 atopic eczema Diseases 0.000 description 3
• 230000009286 beneficial effect Effects 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 230000003915 cell function Effects 0.000 description 3
• 239000011248 coating agent Substances 0.000 description 3
• OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 3
• 230000007547 defect Effects 0.000 description 3
• 235000005911 diet Nutrition 0.000 description 3
• 230000037213 diet Effects 0.000 description 3
• 229910001882 dioxygen Inorganic materials 0.000 description 3
• 230000003203 everyday effect Effects 0.000 description 3
• 239000010419 fine particle Substances 0.000 description 3
• 235000013355 food flavoring agent Nutrition 0.000 description 3
• 239000008103 glucose Substances 0.000 description 3
• 235000011187 glycerol Nutrition 0.000 description 3
• 239000003102 growth factor Substances 0.000 description 3
• 230000036541 health Effects 0.000 description 3
• 230000001900 immune effect Effects 0.000 description 3
• 230000001976 improved effect Effects 0.000 description 3
• 238000010348 incorporation Methods 0.000 description 3
• 208000015181 infectious disease Diseases 0.000 description 3
• 210000004969 inflammatory cell Anatomy 0.000 description 3
• 230000003993 interaction Effects 0.000 description 3
• 230000009545 invasion Effects 0.000 description 3
• 230000033001 locomotion Effects 0.000 description 3
• 239000011777 magnesium Substances 0.000 description 3
• 239000011159 matrix material Substances 0.000 description 3
• 210000000274 microglia Anatomy 0.000 description 3
• 239000004005 microsphere Substances 0.000 description 3
• 239000002674 ointment Substances 0.000 description 3
• 238000012261 overproduction Methods 0.000 description 3
• 125000004430 oxygen atom Chemical group O* 0.000 description 3
• 238000007911 parenteral administration Methods 0.000 description 3
• 239000002304 perfume Substances 0.000 description 3
• 230000035790 physiological processes and functions Effects 0.000 description 3
• 230000036470 plasma concentration Effects 0.000 description 3
• 239000013641 positive control Substances 0.000 description 3
• 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 3
• 238000007634 remodeling Methods 0.000 description 3
• 230000008439 repair process Effects 0.000 description 3
• 230000036303 septic shock Effects 0.000 description 3
• 230000000405 serological effect Effects 0.000 description 3
• 230000019491 signal transduction Effects 0.000 description 3
• 239000011734 sodium Substances 0.000 description 3
• 238000003860 storage Methods 0.000 description 3
• 239000007929 subcutaneous injection Substances 0.000 description 3
• 238000010254 subcutaneous injection Methods 0.000 description 3
• 239000000758 substrate Substances 0.000 description 3
• 239000000829 suppository Substances 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• 238000012546 transfer Methods 0.000 description 3
• 230000002792 vascular Effects 0.000 description 3
• 230000024883 vasodilation Effects 0.000 description 3
• 230000035899 viability Effects 0.000 description 3
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
• SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 2
• DVKQVRZMKBDMDH-UUOKFMHZSA-N 8-Br-cAMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1Br DVKQVRZMKBDMDH-UUOKFMHZSA-N 0.000 description 2
• 208000023769 AA amyloidosis Diseases 0.000 description 2
• 244000215068 Acacia senegal Species 0.000 description 2
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
• 108700028369 Alleles Proteins 0.000 description 2
• 208000019901 Anxiety disease Diseases 0.000 description 2
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
• 201000001320 Atherosclerosis Diseases 0.000 description 2
• XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 2
• XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 2
• 241000894006 Bacteria Species 0.000 description 2
• 201000006474 Brain Ischemia Diseases 0.000 description 2
• 102100032366 C-C motif chemokine 7 Human genes 0.000 description 2
• 101710155834 C-C motif chemokine 7 Proteins 0.000 description 2
• 102100032937 CD40 ligand Human genes 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
• 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
• 206010008120 Cerebral ischaemia Diseases 0.000 description 2
• 229920001076 Cutan Polymers 0.000 description 2
• 208000000059 Dyspnea Diseases 0.000 description 2
• 206010013975 Dyspnoeas Diseases 0.000 description 2
• 102400001368 Epidermal growth factor Human genes 0.000 description 2
• 101800003838 Epidermal growth factor Proteins 0.000 description 2
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
• 229920000084 Gum arabic Polymers 0.000 description 2
• 206010019233 Headaches Diseases 0.000 description 2
• 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
• 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
• 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 2
• 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 2
• 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 description 2
• 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 2
• 101000804764 Homo sapiens Lymphotactin Proteins 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• 102000026633 IL6 Human genes 0.000 description 2
• 206010062016 Immunosuppression Diseases 0.000 description 2
• 108010041012 Integrin alpha4 Proteins 0.000 description 2
• 102000006992 Interferon-alpha Human genes 0.000 description 2
• 108010047761 Interferon-alpha Proteins 0.000 description 2
• 102100039065 Interleukin-1 beta Human genes 0.000 description 2
• 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 2
• 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 2
• 102000003814 Interleukin-10 Human genes 0.000 description 2
• 108090000174 Interleukin-10 Proteins 0.000 description 2
• 102000003815 Interleukin-11 Human genes 0.000 description 2
• 108090000177 Interleukin-11 Proteins 0.000 description 2
• 108010002386 Interleukin-3 Proteins 0.000 description 2
• 108010002586 Interleukin-7 Proteins 0.000 description 2
• 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 2
• 102000015696 Interleukins Human genes 0.000 description 2
• 108010063738 Interleukins Proteins 0.000 description 2
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
• 240000007472 Leucaena leucocephala Species 0.000 description 2
• 102100035304 Lymphotactin Human genes 0.000 description 2
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
• 239000004472 Lysine Substances 0.000 description 2
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
• 102000009073 Macrophage Migration-Inhibitory Factors Human genes 0.000 description 2
• 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 description 2
• 102100030417 Matrilysin Human genes 0.000 description 2
• 206010027476 Metastases Diseases 0.000 description 2
• 241000699660 Mus musculus Species 0.000 description 2
• 206010060860 Neurological symptom Diseases 0.000 description 2
• 108010005298 Oligodendrocyte-Myelin Glycoprotein Proteins 0.000 description 2
• 102100026746 Oligodendrocyte-myelin glycoprotein Human genes 0.000 description 2
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• 102000016611 Proteoglycans Human genes 0.000 description 2
• 108010067787 Proteoglycans Proteins 0.000 description 2
• 238000002123 RNA extraction Methods 0.000 description 2
• 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
• 206010039811 Secondary amyloidosis Diseases 0.000 description 2
• 206010041662 Splinter Diseases 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
• 230000006052 T cell proliferation Effects 0.000 description 2
• 210000004241 Th2 cell Anatomy 0.000 description 2
• 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 2
• 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 description 2
• 208000025865 Ulcer Diseases 0.000 description 2
• 206010047700 Vomiting Diseases 0.000 description 2
• 235000010489 acacia gum Nutrition 0.000 description 2
• 239000000205 acacia gum Substances 0.000 description 2
• 235000004279 alanine Nutrition 0.000 description 2
• 230000000172 allergic effect Effects 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
• 229940124599 anti-inflammatory drug Drugs 0.000 description 2
• 229940053195 antiepileptics hydantoin derivative Drugs 0.000 description 2
• 230000036506 anxiety Effects 0.000 description 2
• 230000006907 apoptotic process Effects 0.000 description 2
• 206010003246 arthritis Diseases 0.000 description 2
• 229960005370 atorvastatin Drugs 0.000 description 2
• 230000006472 autoimmune response Effects 0.000 description 2
• 230000005784 autoimmunity Effects 0.000 description 2
• 230000006399 behavior Effects 0.000 description 2
• SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
• 230000002146 bilateral effect Effects 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 238000004820 blood count Methods 0.000 description 2
• 230000036765 blood level Effects 0.000 description 2
• 206010006451 bronchitis Diseases 0.000 description 2
• 239000006172 buffering agent Substances 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 239000001569 carbon dioxide Substances 0.000 description 2
• 229910002092 carbon dioxide Inorganic materials 0.000 description 2
• 239000006143 cell culture medium Substances 0.000 description 2
• 230000012292 cell migration Effects 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 235000010980 cellulose Nutrition 0.000 description 2
• 206010008118 cerebral infarction Diseases 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 239000005482 chemotactic factor Substances 0.000 description 2
• 238000002512 chemotherapy Methods 0.000 description 2
• 235000019504 cigarettes Nutrition 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 229940110456 cocoa butter Drugs 0.000 description 2
• 235000019868 cocoa butter Nutrition 0.000 description 2
• 230000001149 cognitive effect Effects 0.000 description 2
• 230000000112 colonic effect Effects 0.000 description 2
• 235000012343 cottonseed oil Nutrition 0.000 description 2
• ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 2
• 230000002380 cytological effect Effects 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 230000008021 deposition Effects 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• 229910003460 diamond Inorganic materials 0.000 description 2
• 238000010790 dilution Methods 0.000 description 2
• 239000012895 dilution Substances 0.000 description 2
• 230000003828 downregulation Effects 0.000 description 2
• 239000003651 drinking water Substances 0.000 description 2
• 235000020188 drinking water Nutrition 0.000 description 2
• 239000012636 effector Substances 0.000 description 2
• 229940116977 epidermal growth factor Drugs 0.000 description 2
• MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
• 210000002744 extracellular matrix Anatomy 0.000 description 2
• 206010016256 fatigue Diseases 0.000 description 2
• 239000012091 fetal bovine serum Substances 0.000 description 2
• 239000000945 filler Substances 0.000 description 2
• 235000019634 flavors Nutrition 0.000 description 2
• 239000006260 foam Substances 0.000 description 2
• 235000003599 food sweetener Nutrition 0.000 description 2
• 235000013922 glutamic acid Nutrition 0.000 description 2
• 239000004220 glutamic acid Substances 0.000 description 2
• 210000004209 hair Anatomy 0.000 description 2
• 231100000869 headache Toxicity 0.000 description 2
• 150000001469 hydantoins Chemical class 0.000 description 2
• 230000002209 hydrophobic effect Effects 0.000 description 2
• 230000036039 immunity Effects 0.000 description 2
• 230000001506 immunosuppresive effect Effects 0.000 description 2
• 238000009169 immunotherapy Methods 0.000 description 2
• 239000003701 inert diluent Substances 0.000 description 2
• 230000008595 infiltration Effects 0.000 description 2
• 238000001764 infiltration Methods 0.000 description 2
• 230000003960 inflammatory cascade Effects 0.000 description 2
• 206010022000 influenza Diseases 0.000 description 2
• 230000004941 influx Effects 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 238000011081 inoculation Methods 0.000 description 2
• 239000002054 inoculum Substances 0.000 description 2
• 210000004692 intercellular junction Anatomy 0.000 description 2
• 102000053460 interleukin-17 receptor activity proteins Human genes 0.000 description 2
• 108040001304 interleukin-17 receptor activity proteins Proteins 0.000 description 2
• 239000011872 intimate mixture Substances 0.000 description 2
• 229910052742 iron Inorganic materials 0.000 description 2
• 210000002510 keratinocyte Anatomy 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 238000011694 lewis rat Methods 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 210000004185 liver Anatomy 0.000 description 2
• 238000011068 loading method Methods 0.000 description 2
• 239000006210 lotion Substances 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• 210000001165 lymph node Anatomy 0.000 description 2
• 235000018977 lysine Nutrition 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 2
• 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 2
• 108020004999 messenger RNA Proteins 0.000 description 2
• 230000009401 metastasis Effects 0.000 description 2
• 230000002025 microglial effect Effects 0.000 description 2
• 230000027939 micturition Effects 0.000 description 2
• 230000004001 molecular interaction Effects 0.000 description 2
• OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 2
• 239000002105 nanoparticle Substances 0.000 description 2
• 210000003928 nasal cavity Anatomy 0.000 description 2
• 238000002663 nebulization Methods 0.000 description 2
• 230000001537 neural effect Effects 0.000 description 2
• 230000000926 neurological effect Effects 0.000 description 2
• 239000002547 new drug Substances 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 235000020660 omega-3 fatty acid Nutrition 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 201000008482 osteoarthritis Diseases 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 230000001575 pathological effect Effects 0.000 description 2
• 230000007170 pathology Effects 0.000 description 2
• 239000008188 pellet Substances 0.000 description 2
• 229910052698 phosphorus Inorganic materials 0.000 description 2
• 239000011574 phosphorus Substances 0.000 description 2
• 230000000704 physical effect Effects 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 238000002360 preparation method Methods 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 235000019833 protease Nutrition 0.000 description 2
• 230000007420 reactivation Effects 0.000 description 2
• 239000003642 reactive oxygen metabolite Substances 0.000 description 2
• 230000009257 reactivity Effects 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 229920006395 saturated elastomer Polymers 0.000 description 2
• 231100000241 scar Toxicity 0.000 description 2
• 230000001235 sensitizing effect Effects 0.000 description 2
• 239000008159 sesame oil Substances 0.000 description 2
• 235000011803 sesame oil Nutrition 0.000 description 2
• 208000013220 shortness of breath Diseases 0.000 description 2
• 210000003491 skin Anatomy 0.000 description 2
• 241000894007 species Species 0.000 description 2
• 238000001228 spectrum Methods 0.000 description 2
• 210000004988 splenocyte Anatomy 0.000 description 2
• 239000007921 spray Substances 0.000 description 2
• 230000006641 stabilisation Effects 0.000 description 2
• 238000011105 stabilization Methods 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 238000007619 statistical method Methods 0.000 description 2
• 210000000130 stem cell Anatomy 0.000 description 2
• 239000011550 stock solution Substances 0.000 description 2
• 230000035882 stress Effects 0.000 description 2
• 235000000346 sugar Nutrition 0.000 description 2
• 230000001629 suppression Effects 0.000 description 2
• 239000003765 sweetening agent Substances 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 235000012222 talc Nutrition 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
• 238000011287 therapeutic dose Methods 0.000 description 2
• 230000008719 thickening Effects 0.000 description 2
• 229940104230 thymidine Drugs 0.000 description 2
• 238000004448 titration Methods 0.000 description 2
• DVKJHBMWWAPEIU-UHFFFAOYSA-N toluene 2,4-diisocyanate Chemical compound CC1=CC=C(N=C=O)C=C1N=C=O DVKJHBMWWAPEIU-UHFFFAOYSA-N 0.000 description 2
• 238000011200 topical administration Methods 0.000 description 2
• 238000013518 transcription Methods 0.000 description 2
• 230000035897 transcription Effects 0.000 description 2
• 238000011830 transgenic mouse model Methods 0.000 description 2
• 210000002993 trophoblast Anatomy 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 235000002374 tyrosine Nutrition 0.000 description 2
• 230000036269 ulceration Effects 0.000 description 2
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
• 230000008673 vomiting Effects 0.000 description 2
• 230000029663 wound healing Effects 0.000 description 2
• HDTRYLNUVZCQOY-UHFFFAOYSA-N &alpha;-D-glucopyranosyl-&alpha;-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
• SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
• FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
• DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
• 229940058015 1,3-butylene glycol Drugs 0.000 description 1
• MZIYRTZAYQIAHW-UHFFFAOYSA-N 1-methyl-8-(2-methylpropyl)-3,7-dihydropurine-2,6-dione Chemical compound N1C(=O)N(C)C(=O)C2=C1N=C(CC(C)C)N2 MZIYRTZAYQIAHW-UHFFFAOYSA-N 0.000 description 1
• 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
• JMTCEFUSRHYJBF-DDJPMISGSA-N 149635-73-4 Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=C(O)C=C1 JMTCEFUSRHYJBF-DDJPMISGSA-N 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• YRSQBSSUBKVERH-UHFFFAOYSA-N 5-(4-phenoxyphenyl)sulfonylpentane-1,2-dithiol Chemical compound C1=CC(S(=O)(=O)CCCC(S)CS)=CC=C1OC1=CC=CC=C1 YRSQBSSUBKVERH-UHFFFAOYSA-N 0.000 description 1
• VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• 108091007504 ADAM10 Proteins 0.000 description 1
• 208000023761 AL amyloidosis Diseases 0.000 description 1
• 208000030090 Acute Disease Diseases 0.000 description 1
• 206010067484 Adverse reaction Diseases 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 201000004384 Alopecia Diseases 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
• 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
• 235000017060 Arachis glabrata Nutrition 0.000 description 1
• 244000105624 Arachis hypogaea Species 0.000 description 1
• 235000010777 Arachis hypogaea Nutrition 0.000 description 1
• 235000018262 Arachis monticola Nutrition 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 206010003694 Atrophy Diseases 0.000 description 1
• 102100039705 Beta-2 adrenergic receptor Human genes 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• 201000004569 Blindness Diseases 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• 208000006386 Bone Resorption Diseases 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• 102000010183 Bradykinin receptor Human genes 0.000 description 1
• 108050001736 Bradykinin receptor Proteins 0.000 description 1
• 206010006458 Bronchitis chronic Diseases 0.000 description 1
• 108010074051 C-Reactive Protein Proteins 0.000 description 1
• 102100032752 C-reactive protein Human genes 0.000 description 1
• 108010029697 CD40 Ligand Proteins 0.000 description 1
• 102000003922 Calcium Channels Human genes 0.000 description 1
• 108090000312 Calcium Channels Proteins 0.000 description 1
• 241000282688 Callicebus Species 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 208000002177 Cataract Diseases 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 206010008190 Cerebrovascular accident Diseases 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 102000012422 Collagen Type I Human genes 0.000 description 1
• 108010022452 Collagen Type I Proteins 0.000 description 1
• 102000029816 Collagenase Human genes 0.000 description 1
• 108060005980 Collagenase Proteins 0.000 description 1
• 102100027995 Collagenase 3 Human genes 0.000 description 1
• 206010010071 Coma Diseases 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 229920000858 Cyclodextrin Polymers 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• 241000701022 Cytomegalovirus Species 0.000 description 1
• 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 230000033616 DNA repair Effects 0.000 description 1
• 230000006820 DNA synthesis Effects 0.000 description 1
• 206010012735 Diarrhoea Diseases 0.000 description 1
• 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
• 108010053187 Diphtheria Toxin Proteins 0.000 description 1
• 102000016607 Diphtheria Toxin Human genes 0.000 description 1
• 102100039673 Disintegrin and metalloproteinase domain-containing protein 10 Human genes 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 102000016942 Elastin Human genes 0.000 description 1
• 108010014258 Elastin Proteins 0.000 description 1
• 108091006149 Electron carriers Proteins 0.000 description 1
• 108030001679 Endothelin-converting enzyme 1 Proteins 0.000 description 1
• 102000048186 Endothelin-converting enzyme 1 Human genes 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• 208000010201 Exanthema Diseases 0.000 description 1
• 208000009386 Experimental Arthritis Diseases 0.000 description 1
• 108091006020 Fc-tagged proteins Proteins 0.000 description 1
• 102000009123 Fibrin Human genes 0.000 description 1
• 108010073385 Fibrin Proteins 0.000 description 1
• BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
• 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
• 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
• 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
• 102100037362 Fibronectin Human genes 0.000 description 1
• 108010067306 Fibronectins Proteins 0.000 description 1
• 108090000852 Forkhead Transcription Factors Proteins 0.000 description 1
• 208000007882 Gastritis Diseases 0.000 description 1
• 102000013382 Gelatinases Human genes 0.000 description 1
• 108010026132 Gelatinases Proteins 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 201000005569 Gout Diseases 0.000 description 1
• 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 1
• 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 1
• 101000577887 Homo sapiens Collagenase 3 Proteins 0.000 description 1
• 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
• 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 1
• 101001011906 Homo sapiens Matrix metalloproteinase-14 Proteins 0.000 description 1
• 101001011884 Homo sapiens Matrix metalloproteinase-15 Proteins 0.000 description 1
• 101001011886 Homo sapiens Matrix metalloproteinase-16 Proteins 0.000 description 1
• 101001011887 Homo sapiens Matrix metalloproteinase-17 Proteins 0.000 description 1
• 101000990908 Homo sapiens Neutrophil collagenase Proteins 0.000 description 1
• 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 1
• 101000577874 Homo sapiens Stromelysin-2 Proteins 0.000 description 1
• 101000713602 Homo sapiens T-box transcription factor TBX21 Proteins 0.000 description 1
• 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
• 101000819074 Homo sapiens Transcription factor GATA-4 Proteins 0.000 description 1
• 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
• 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• 208000001953 Hypotension Diseases 0.000 description 1
• 108060003951 Immunoglobulin Proteins 0.000 description 1
• 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 description 1
• 208000020060 Increased inflammatory response Diseases 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• 206010022095 Injection Site reaction Diseases 0.000 description 1
• 102100022338 Integrin alpha-M Human genes 0.000 description 1
• 102100026720 Interferon beta Human genes 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
• 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
• 102000004554 Interleukin-17 Receptors Human genes 0.000 description 1
• 108010017525 Interleukin-17 Receptors Proteins 0.000 description 1
• 108010082786 Interleukin-1alpha Proteins 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• 206010023644 Lacrimation increased Diseases 0.000 description 1
• 239000004166 Lanolin Substances 0.000 description 1
• 108090001090 Lectins Proteins 0.000 description 1
• 102000004856 Lectins Human genes 0.000 description 1
• 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
• 108060001084 Luciferase Proteins 0.000 description 1
• 239000005089 Luciferase Substances 0.000 description 1
• 102100037611 Lysophospholipase Human genes 0.000 description 1
• 241000282553 Macaca Species 0.000 description 1
• 241000282560 Macaca mulatta Species 0.000 description 1
• 108030001712 Macrophage elastases Proteins 0.000 description 1
• 101710187853 Macrophage metalloelastase Proteins 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
• 108090000855 Matrilysin Proteins 0.000 description 1
• 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
• 108010076501 Matrix Metalloproteinase 12 Proteins 0.000 description 1
• 102100030216 Matrix metalloproteinase-14 Human genes 0.000 description 1
• 102100030201 Matrix metalloproteinase-15 Human genes 0.000 description 1
• 102100030200 Matrix metalloproteinase-16 Human genes 0.000 description 1
• 102100030219 Matrix metalloproteinase-17 Human genes 0.000 description 1
• 201000009906 Meningitis Diseases 0.000 description 1
• 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
• 101150101095 Mmp12 gene Proteins 0.000 description 1
• UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
• 208000016285 Movement disease Diseases 0.000 description 1
• 206010048393 Multiple sclerosis relapse Diseases 0.000 description 1
• 208000002740 Muscle Rigidity Diseases 0.000 description 1
• 241001049988 Mycobacterium tuberculosis H37Ra Species 0.000 description 1
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
• 238000005481 NMR spectroscopy Methods 0.000 description 1
• 206010029113 Neovascularisation Diseases 0.000 description 1
• 102000015336 Nerve Growth Factor Human genes 0.000 description 1
• 206010063663 Neuropsychiatric lupus Diseases 0.000 description 1
• 102100030411 Neutrophil collagenase Human genes 0.000 description 1
• 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
• 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
• 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
• 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
• 241000047703 Nonion Species 0.000 description 1
• 240000007817 Olea europaea Species 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 208000010191 Osteitis Deformans Diseases 0.000 description 1
• 102000004264 Osteopontin Human genes 0.000 description 1
• 108010081689 Osteopontin Proteins 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• 102100039467 P3 protein Human genes 0.000 description 1
• 101710117080 P3 protein Proteins 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 208000027868 Paget disease Diseases 0.000 description 1
• 208000037273 Pathologic Processes Diseases 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 206010034650 Peritoneal adhesions Diseases 0.000 description 1
• 239000004264 Petrolatum Substances 0.000 description 1
• 206010057249 Phagocytosis Diseases 0.000 description 1
• 108010058864 Phospholipases A2 Proteins 0.000 description 1
• 206010035039 Piloerection Diseases 0.000 description 1
• 102000004211 Platelet factor 4 Human genes 0.000 description 1
• 108090000778 Platelet factor 4 Proteins 0.000 description 1
• 206010035664 Pneumonia Diseases 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• 206010036673 Primary amyloidosis Diseases 0.000 description 1
• 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
• 108010050808 Procollagen Proteins 0.000 description 1
• 206010036790 Productive cough Diseases 0.000 description 1
• 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
• 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
• 108010010974 Proteolipids Proteins 0.000 description 1
• 102000016202 Proteolipids Human genes 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 239000012979 RPMI medium Substances 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 108700008625 Reporter Genes Proteins 0.000 description 1
• 206010057190 Respiratory tract infections Diseases 0.000 description 1
• 208000025747 Rheumatic disease Diseases 0.000 description 1
• 235000019485 Safflower oil Nutrition 0.000 description 1
• 241001466077 Salina Species 0.000 description 1
• 206010039424 Salivary hypersecretion Diseases 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 description 1
• 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 description 1
• 239000004147 Sorbitan trioleate Substances 0.000 description 1
• PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
• 102100030416 Stromelysin-1 Human genes 0.000 description 1
• 102100028848 Stromelysin-2 Human genes 0.000 description 1
• 101001018322 Sus scrofa Myelin basic protein Proteins 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 230000005867 T cell response Effects 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 102100036840 T-box transcription factor TBX21 Human genes 0.000 description 1
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
• 101710120037 Toxin CcdB Proteins 0.000 description 1
• 102100021380 Transcription factor GATA-4 Human genes 0.000 description 1
• 108010009583 Transforming Growth Factors Proteins 0.000 description 1
• 102000009618 Transforming Growth Factors Human genes 0.000 description 1
• 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
• 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
• 206010044565 Tremor Diseases 0.000 description 1
• 108060005989 Tryptase Proteins 0.000 description 1
• 102000001400 Tryptase Human genes 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
• 206010064390 Tumour invasion Diseases 0.000 description 1
• 206010054094 Tumour necrosis Diseases 0.000 description 1
• 108090000848 Ubiquitin Proteins 0.000 description 1
• 102000044159 Ubiquitin Human genes 0.000 description 1
• 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
• 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
• 206010047141 Vasodilatation Diseases 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
• 230000003187 abdominal effect Effects 0.000 description 1
• 230000001594 aberrant effect Effects 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• 239000002253 acid Substances 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 208000024716 acute asthma Diseases 0.000 description 1
• 230000010398 acute inflammatory response Effects 0.000 description 1
• 230000004721 adaptive immunity Effects 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 239000000853 adhesive Substances 0.000 description 1
• 230000001070 adhesive effect Effects 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 230000006838 adverse reaction Effects 0.000 description 1
• 239000004479 aerosol dispenser Substances 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 108010003059 aggrecanase Proteins 0.000 description 1
• 230000032683 aging Effects 0.000 description 1
• 238000013019 agitation Methods 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 210000005058 airway cell Anatomy 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• 239000013566 allergen Substances 0.000 description 1
• 230000000735 allogeneic effect Effects 0.000 description 1
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
• MHCAFGMQMCSRGH-UHFFFAOYSA-N aluminum;hydrate Chemical compound O.[Al] MHCAFGMQMCSRGH-UHFFFAOYSA-N 0.000 description 1
• 210000001132 alveolar macrophage Anatomy 0.000 description 1
• 239000012080 ambient air Substances 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 230000005167 amoeboid movement Effects 0.000 description 1
• 230000003872 anastomosis Effects 0.000 description 1
• 230000002424 anti-apoptotic effect Effects 0.000 description 1
• 230000000078 anti-malarial effect Effects 0.000 description 1
• 230000000845 anti-microbial effect Effects 0.000 description 1
• 230000005809 anti-tumor immunity Effects 0.000 description 1
• 229910052786 argon Inorganic materials 0.000 description 1
• 238000003491 array Methods 0.000 description 1
• 230000004872 arterial blood pressure Effects 0.000 description 1
• 238000003149 assay kit Methods 0.000 description 1
• 230000003143 atherosclerotic effect Effects 0.000 description 1
• 125000004429 atom Chemical group 0.000 description 1
• 150000001519 atomic cations Chemical class 0.000 description 1
• 230000037444 atrophy Effects 0.000 description 1
• 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
• 230000002567 autonomic effect Effects 0.000 description 1
• 230000003376 axonal effect Effects 0.000 description 1
• 239000011324 bead Substances 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 235000012216 bentonite Nutrition 0.000 description 1
• 229960002903 benzyl benzoate Drugs 0.000 description 1
• 239000002876 beta blocker Substances 0.000 description 1
• 229940097320 beta blocking agent Drugs 0.000 description 1
• 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 230000002457 bidirectional effect Effects 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 238000004159 blood analysis Methods 0.000 description 1
• 230000023555 blood coagulation Effects 0.000 description 1
• 230000036770 blood supply Effects 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 230000024279 bone resorption Effects 0.000 description 1
• 239000005388 borosilicate glass Substances 0.000 description 1
• 208000029028 brain injury Diseases 0.000 description 1
• 108010059485 brain synaptic membrane glycoprotein gp 50 Proteins 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 244000309464 bull Species 0.000 description 1
• 235000019437 butane-1,3-diol Nutrition 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 235000012241 calcium silicate Nutrition 0.000 description 1
• 230000003185 calcium uptake Effects 0.000 description 1
• 230000009400 cancer invasion Effects 0.000 description 1
• 235000011089 carbon dioxide Nutrition 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 230000003683 cardiac damage Effects 0.000 description 1
• 208000006170 carotid stenosis Diseases 0.000 description 1
• 239000012159 carrier gas Substances 0.000 description 1
• 239000004359 castor oil Substances 0.000 description 1
• 235000019438 castor oil Nutrition 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 230000006037 cell lysis Effects 0.000 description 1
• 210000002390 cell membrane structure Anatomy 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 229920002301 cellulose acetate Polymers 0.000 description 1
• 210000003710 cerebral cortex Anatomy 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 230000035605 chemotaxis Effects 0.000 description 1
• 229940112822 chewing gum Drugs 0.000 description 1
• 235000015218 chewing gum Nutrition 0.000 description 1
• KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical class F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
• BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 1
• 229910052804 chromium Inorganic materials 0.000 description 1
• 208000007451 chronic bronchitis Diseases 0.000 description 1
• 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 230000007012 clinical effect Effects 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 230000024203 complement activation Effects 0.000 description 1
• 230000000295 complement effect Effects 0.000 description 1
• 238000009833 condensation Methods 0.000 description 1
• 230000005494 condensation Effects 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 230000036461 convulsion Effects 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 239000002285 corn oil Substances 0.000 description 1
• 235000005687 corn oil Nutrition 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 210000004087 cornea Anatomy 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 230000000875 corresponding effect Effects 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 229940111134 coxibs Drugs 0.000 description 1
• 230000009193 crawling Effects 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 229940097362 cyclodextrins Drugs 0.000 description 1
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 230000016396 cytokine production Effects 0.000 description 1
• 102000003675 cytokine receptors Human genes 0.000 description 1
• 108010057085 cytokine receptors Proteins 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 239000002254 cytotoxic agent Substances 0.000 description 1
• 231100000599 cytotoxic agent Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 238000011157 data evaluation Methods 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 230000018044 dehydration Effects 0.000 description 1
• 238000006297 dehydration reaction Methods 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 230000003831 deregulation Effects 0.000 description 1
• 230000001066 destructive effect Effects 0.000 description 1
• 230000006866 deterioration Effects 0.000 description 1
• AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
• PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
• 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
• 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
• 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 238000009792 diffusion process Methods 0.000 description 1
• IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
• 238000007865 diluting Methods 0.000 description 1
• XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
• 229960002986 dinoprostone Drugs 0.000 description 1
• FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 229960003722 doxycycline Drugs 0.000 description 1
• 239000008298 dragée Substances 0.000 description 1
• 239000006196 drop Substances 0.000 description 1
• 239000003596 drug target Substances 0.000 description 1
• 230000008846 dynamic interplay Effects 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 230000000668 effect on calcium Effects 0.000 description 1
• 230000002500 effect on skin Effects 0.000 description 1
• 229920002549 elastin Polymers 0.000 description 1
• 230000005672 electromagnetic field Effects 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 230000013020 embryo development Effects 0.000 description 1
• 230000032692 embryo implantation Effects 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 201000002491 encephalomyelitis Diseases 0.000 description 1
• 210000003989 endothelium vascular Anatomy 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 210000003979 eosinophil Anatomy 0.000 description 1
• 230000002327 eosinophilic effect Effects 0.000 description 1
• 210000001339 epidermal cell Anatomy 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 229940093499 ethyl acetate Drugs 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
• 201000005884 exanthem Diseases 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 238000004880 explosion Methods 0.000 description 1
• 210000001508 eye Anatomy 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 230000035558 fertility Effects 0.000 description 1
• 229950003499 fibrin Drugs 0.000 description 1
• 229940126864 fibroblast growth factor Drugs 0.000 description 1
• 238000011049 filling Methods 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• 210000000497 foam cell Anatomy 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 238000004186 food analysis Methods 0.000 description 1
• 230000005021 gait Effects 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 238000001415 gene therapy Methods 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 208000007565 gingivitis Diseases 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 229940076085 gold Drugs 0.000 description 1
• 230000036449 good health Effects 0.000 description 1
• 208000035474 group of disease Diseases 0.000 description 1
• JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
• 208000024963 hair loss Diseases 0.000 description 1
• 230000003676 hair loss Effects 0.000 description 1
• 230000003862 health status Effects 0.000 description 1
• 239000001307 helium Substances 0.000 description 1
• 229910052734 helium Inorganic materials 0.000 description 1
• SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
• 210000002443 helper t lymphocyte Anatomy 0.000 description 1
• 210000000548 hind-foot Anatomy 0.000 description 1
• 229960001340 histamine Drugs 0.000 description 1
• 239000000017 hydrogel Substances 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 230000005661 hydrophobic surface Effects 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 230000036543 hypotension Effects 0.000 description 1
• 230000008105 immune reaction Effects 0.000 description 1
• 230000006058 immune tolerance Effects 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 230000002163 immunogen Effects 0.000 description 1
• 102000018358 immunoglobulin Human genes 0.000 description 1
• 229940088592 immunologic factor Drugs 0.000 description 1
• 239000000367 immunologic factor Substances 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 239000011261 inert gas Substances 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 208000013256 infectious meningitis Diseases 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 229940125369 inhaled corticosteroids Drugs 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 229940047124 interferons Drugs 0.000 description 1
• 229940047122 interleukins Drugs 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 239000005433 ionosphere Substances 0.000 description 1
• 230000007794 irritation Effects 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
• 235000015110 jellies Nutrition 0.000 description 1
• 239000008274 jelly Substances 0.000 description 1
• 229910052743 krypton Inorganic materials 0.000 description 1
• DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 description 1
• 230000004317 lacrimation Effects 0.000 description 1
• 235000019388 lanolin Nutrition 0.000 description 1
• 229940039717 lanolin Drugs 0.000 description 1
• 230000002045 lasting effect Effects 0.000 description 1
• 230000013016 learning Effects 0.000 description 1
• 239000002523 lectin Substances 0.000 description 1
• VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
• 229960000681 leflunomide Drugs 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 235000011475 lollipops Nutrition 0.000 description 1
• 230000005923 long-lasting effect Effects 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 210000003141 lower extremity Anatomy 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 230000001926 lymphatic effect Effects 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
• 239000000347 magnesium hydroxide Substances 0.000 description 1
• 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 230000005291 magnetic effect Effects 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 208000027202 mammary Paget disease Diseases 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 108020004084 membrane receptors Proteins 0.000 description 1
• 210000003071 memory t lymphocyte Anatomy 0.000 description 1
• 230000005906 menstruation Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
• 229960004584 methylprednisolone Drugs 0.000 description 1
• 239000004530 micro-emulsion Substances 0.000 description 1
• 238000002493 microarray Methods 0.000 description 1
• 230000000813 microbial effect Effects 0.000 description 1
• 229960004023 minocycline Drugs 0.000 description 1
• 230000002297 mitogenic effect Effects 0.000 description 1
• CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
• 229960005127 montelukast Drugs 0.000 description 1
• 238000000465 moulding Methods 0.000 description 1
• 210000004400 mucous membrane Anatomy 0.000 description 1
• 210000003007 myelin sheath Anatomy 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• 239000002101 nanobubble Substances 0.000 description 1
• 239000007923 nasal drop Substances 0.000 description 1
• 229940100662 nasal drops Drugs 0.000 description 1
• 239000007922 nasal spray Substances 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
• 229910052754 neon Inorganic materials 0.000 description 1
• GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
• 230000009826 neoplastic cell growth Effects 0.000 description 1
• 230000009251 neurologic dysfunction Effects 0.000 description 1
• 208000015015 neurological dysfunction Diseases 0.000 description 1
• 230000003961 neuronal insult Effects 0.000 description 1
• 229910052759 nickel Inorganic materials 0.000 description 1
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
• 210000004940 nucleus Anatomy 0.000 description 1
• 231100000862 numbness Toxicity 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 210000004248 oligodendroglia Anatomy 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 229940012843 omega-3 fatty acid Drugs 0.000 description 1
• 239000006014 omega-3 oil Substances 0.000 description 1
• 238000001543 one-way ANOVA Methods 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 230000011164 ossification Effects 0.000 description 1
• 210000002997 osteoclast Anatomy 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-O oxonium Chemical compound [OH3+] XLYOFNOQVPJJNP-UHFFFAOYSA-O 0.000 description 1
• 238000002559 palpation Methods 0.000 description 1
• 229960005489 paracetamol Drugs 0.000 description 1
• 230000005298 paramagnetic effect Effects 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 230000009054 pathological process Effects 0.000 description 1
• 235000020232 peanut Nutrition 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 229960001412 pentobarbital Drugs 0.000 description 1
• WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
• 230000010412 perfusion Effects 0.000 description 1
• 208000028169 periodontal disease Diseases 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 210000001428 peripheral nervous system Anatomy 0.000 description 1
• 230000036581 peripheral resistance Effects 0.000 description 1
• 230000035699 permeability Effects 0.000 description 1
• 235000019271 petrolatum Nutrition 0.000 description 1
• 229940066842 petrolatum Drugs 0.000 description 1
• 230000008782 phagocytosis Effects 0.000 description 1
• 239000008024 pharmaceutical diluent Substances 0.000 description 1
• 230000003285 pharmacodynamic effect Effects 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 230000001766 physiological effect Effects 0.000 description 1
• 230000005371 pilomotor reflex Effects 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 229940068917 polyethylene glycols Drugs 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 229920001296 polysiloxane Polymers 0.000 description 1
• 239000011148 porous material Substances 0.000 description 1
• 208000027147 post-infectious syndrome Diseases 0.000 description 1
• 230000002980 postoperative effect Effects 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 230000036544 posture Effects 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 238000004321 preservation Methods 0.000 description 1
• 239000000047 product Substances 0.000 description 1
• 230000007114 proinflammatory cascade Effects 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 229960004063 propylene glycol Drugs 0.000 description 1
• XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
• 235000019419 proteases Nutrition 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
• 210000001747 pupil Anatomy 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 206010037844 rash Diseases 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000003014 reinforcing effect Effects 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
• 208000037803 restenosis Diseases 0.000 description 1
• 238000003757 reverse transcription PCR Methods 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 201000003068 rheumatic fever Diseases 0.000 description 1
• 206010039083 rhinitis Diseases 0.000 description 1
• 239000003813 safflower oil Substances 0.000 description 1
• 235000005713 safflower oil Nutrition 0.000 description 1
• 208000026451 salivation Diseases 0.000 description 1
• 230000037390 scarring Effects 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 208000017520 skin disease Diseases 0.000 description 1
• 206010040882 skin lesion Diseases 0.000 description 1
• 231100000444 skin lesion Toxicity 0.000 description 1
• 230000007958 sleep Effects 0.000 description 1
• 239000000779 smoke Substances 0.000 description 1
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 125000004436 sodium atom Chemical group 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• 239000008279 sol Substances 0.000 description 1
• 239000012453 solvate Substances 0.000 description 1
• 235000019337 sorbitan trioleate Nutrition 0.000 description 1
• 229960000391 sorbitan trioleate Drugs 0.000 description 1
• 238000001179 sorption measurement Methods 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 210000004989 spleen cell Anatomy 0.000 description 1
• 208000024794 sputum Diseases 0.000 description 1
• 210000003802 sputum Anatomy 0.000 description 1
• 229910001220 stainless steel Inorganic materials 0.000 description 1
• 239000010935 stainless steel Substances 0.000 description 1
• 238000012289 standard assay Methods 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 108091007196 stromelysin Proteins 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 239000002511 suppository base Substances 0.000 description 1
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 210000000225 synapse Anatomy 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 230000009897 systematic effect Effects 0.000 description 1
• 229940037128 systemic glucocorticoids Drugs 0.000 description 1
• 238000010998 test method Methods 0.000 description 1
• 229940072172 tetracycline antibiotic Drugs 0.000 description 1
• BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
• 230000004797 therapeutic response Effects 0.000 description 1
• 230000005919 time-dependent effect Effects 0.000 description 1
• 230000009772 tissue formation Effects 0.000 description 1
• 230000007838 tissue remodeling Effects 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 229910052723 transition metal Inorganic materials 0.000 description 1
• 229910001428 transition metal ion Inorganic materials 0.000 description 1
• 150000003624 transition metals Chemical class 0.000 description 1
• FFSJPOPLSWBGQY-UHFFFAOYSA-N triazol-4-one Chemical class O=C1C=NN=N1 FFSJPOPLSWBGQY-UHFFFAOYSA-N 0.000 description 1
• CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
• 229940029284 trichlorofluoromethane Drugs 0.000 description 1
• 230000001228 trophic effect Effects 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 241000712461 unidentified influenza virus Species 0.000 description 1
• 238000012762 unpaired Student’s t-test Methods 0.000 description 1
• 210000001364 upper extremity Anatomy 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 238000009834 vaporization Methods 0.000 description 1
• 230000008016 vaporization Effects 0.000 description 1
• 210000001631 vena cava inferior Anatomy 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 239000011800 void material Substances 0.000 description 1
• 239000000341 volatile oil Substances 0.000 description 1
• 230000002747 voluntary effect Effects 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 239000002351 wastewater Substances 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 239000002023 wood Substances 0.000 description 1
• 230000010388 wound contraction Effects 0.000 description 1
• 229910052724 xenon Inorganic materials 0.000 description 1
• FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
• 229960004764 zafirlukast Drugs 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1